Impact of Recurrence Score on type and duration of chemotherapy in breast cancer.

ABSTRACT:

Background

The use of Oncotype dx (Genomic Health, Redwood City, CA, U.S.A.) testing has been shown to change treatment decisions in approximately 30% of breast cancer (bca) cases, but research on how Recurrence Score testing has affected the type of chemotherapy offered is limited. We sought to determine if the availability of Oncotype dx testing resulted in a change to the type and duration of chemotherapy regimens used in the treatment of early-stage hormone receptor-positive bca.

Methods

In a population-based cohort study, patients treated in the 2 years before the availability of Oncotype dx testing were compared with patients treated in the 2 years after testing availability. Charts were audited and divided into 2 groups: pre-Oncotype dx and post-Oncotype dx. The group

SUBMITTER: Willemsma K 

PROVIDER: S-EPMC7253753 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature